EGFR-TKI led to increased PD-L1 expression from 14% at baseline to 28% of patients, accompanied by higher tumour mutational burden, a measure of how many mutations per megabase of genome the tumour has managed to accumulate. The gene discussed is CD274; the disease is neoplasm.